Treatment for Chronic Hepatitis C: Experimental Treatments

A ONE YEAR RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF ROSIGLITAZONE IN NON ALCOHOLIC STEATOHEPATITIS: RESULTS OF THE FLIRT PILOT TRIAL
V Ratziu. Abstract 738.

EFFICACY AND SAFETY OF ELTROMBOPAG, AN ORAL PLATELET GROWTH FACTOR, IN SUBJECTS WITH HCV ASSOCIATED THROMBOCYTOPENIA: PRELIMINARY RESULTS FROM A PHASE II DOSE-RANGING STUDY
J G McHutchison. Abstract 745.

PRECLINICAL CHARACTERISTICS OF ITMN-B, AN ORALLY ACTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE NOMINATED FOR PRECLINICAL DEVELOPMENT
S D Seiwert. Abstract 750.

EARLY CLEARANCE OF HCV RNA WITH VALOPICITABINE (NM283) PLUS PEG-INTERFERON IN TREATMENT-NAÏVE PATIENTS WITH HCV-1 INFECTION: FIRST RESULTS FROM A PHASE IIB TRIAL
D Dieterich. Abstract 736.

INITIAL RESULTS OF A 14-DAY STUDY OF THE HEPATITIS C VIRUS INHIBITOR PROTEASE VX-950, IN COMBINATION WITH PEGINTERFERON-ALFA-2A
HW Reesink. Abstract 737.

EARLY VIRAL RESPONSE TO CPG 10101, IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN, IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSE RESPONSE
J G McHutchison. Abstract 730.

INTERIM RESULTS OF A MULTIPLE ASCENDING DOSE STUDY OF R1626, A NOVEL NUCLEOSIDE ANALOG TARGETING HCV POLYMERASE IN CHRONIC HCV PATIENTS
S Roberts. Abstract 731.

INTERIM (WEEK 12) PHASE 2B VIROLOGICAL EFFICACY AND SAFETY RESULTS OF ALBUMIN INTERFERON ALFA-2B COMBINED WITH RIBAVIRIN IN GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
S Zeuzem. Abstract 733.

THE SAFETY AND EFFICACY OF VIRAMIDINE® PLUS PEGYLATED INTERFERON ALFA-2B VERSUS RIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2B IN THERAPY-NAÏVE PATIENTS INFECTED WITH HCV: PHASE 3 RESULTS    [ SLIDES in PDF Format ]
Y Benhamou. Abstract 751.

VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN HEPATITIS C PATIENTS WITH PRIOR NON-RESPONSE TO PEGIFN/RBV: WEEK 24 RESULTS  
H Zhao. Abstract 43 (Oral).

THE HCV NS3 PROTEASE INHIBITOR SCH 503034 IN COMBINATION WITH PEG-IFN-ALPHA-2B IN THE TREATMENT OF HCV-1 PEG-IFN-ALPHA-2B NON-RESPONDERS: ANTIVIRAL ACTIVITY AND HCV VARIANT ANALYSIS  

S Zeuzem . Abstract 78 (Oral).  

PHARMACOKINETIC BOOSTING OF VX-950, AN INHIBITOR OF HCV PROTEASE, BY CO-DOSING WITH RITONAVIR   
D J Kempf. Abstract 4.

LONG-TERM STUDY OF NM283 (VALOPICITABINE) RESISTANCE USING BOVINE VIRAL DIARRHEA VIRUS
V Bichko. Abstract 403.